// App-Quantinova.ai

1502 : The CD19 Antibody MOR208 Efficiently Triggers Natural Killer Cell-Mediated Cytotoxicity Against Acute Lymphoblastic Leukemia Cells From Pediatric and Adult Patients

Researchers

Presenter

  • Eugene A Zhukovsky

Principal Investigators

  • Monika Bruggemann

  • Michael Kneba

  • Andre Schrauder

  • Martin Schrappe

  • Roland Repp

  • Andreas Humpe

  • Martin Gramatzki

  • Matthias Peipp

Medical Centers

  • Department of Medicine, University Medical Center Schleswig-Holstein, Kiel, Germany

  • Division of Stem Cell Transplantation and Immunotherapy, nd Department of Medicine, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany

  • Department of General Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany

Locations

  • Germany

Companies

  • Xencor Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Lymphocytic Leukemia

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Natural Killer cells

  • Cluster of differentiation 69

Drug/Treatment

  • XmAb5574

  • Tafasitamab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved